The American Joint Committee on Cancer's Cancer Staging Manual is used by physicians throughout the world to diagnose cancer and determine the extent to which cancer has progressed. All of the TNM staging information included in this Sixth Edition is uniform between the AJCC (American Joint Committee on Cancer) and the UICC (International Union Against Cancer). In addition to the information found in the Handbook, the Manual provides standardized data forms for each anatomic site, which can be utilized as permanent patient records, enabling clinicians and cancer research scientists to maintain consistency in evaluating the efficacy of diagnosis and treatment. The CD-ROM packaged with each Manual contains printable copies of each of the book’s 45 Staging Forms.

Confronted with myriads ofTs, N's and M's in the VICC TNM booklet, classifying a malignancy may seem to many cancer clini cians a tedious, dull and pedantic task. But then when he looks into the TNM-Atlas all of a sudden lifeless categories become vi vid images, challenging his know-how and his investigational skills. Prof. Dr. Brigit van der Werf-Messing, Chairman of the International TNM-Committee of the VICC. Preface In 1938 the League of Nations Health Organization published an "Atlas illustrating the division of cancer of the uterine cervix into four stages according to the anatomo-clinical extent of the growth". Since this work appeared, the idea of visual representation of the anatomical extent of malignant tumours at the different stages of their development has been repeatedly discussed. At its meeting in Copenhagen in July 1954, the VICC adopted as part of its programme "the realization of a clinical atlas". However, the time to do the planned illustration work was not ripe until the National Committees and international organiza tions had officially recognized the 28 classifications of malignant tumours at various sites as presented in the 3rd edition of the "TNM Booklet" (1978) edited by M. Harmer. This was all the more important since in 1980, in addition to the "Booklet", a "Brochure of Checklists" edited by A.H. Sellers was made available as a further aid in the practical application of the TNMsystem

Significantly expanded, expertly and beautifully illustrated, The AJCC Cancer Staging Atlas, 2nd Edition, offers more than 600 illustrations created exclusively for this new edition and is fully updated to reflect the concepts discussed in the 7th Edition of both the AJCC Cancer Staging Manual and its companion Handbook. This Atlas illustrates the TNM classifications of all cancer sites and types included in the 7th Edition of the Manual and visually conceptualizes the TNM classifications and stage groupings. Specifically designed for simplicity and precision, the drawings have been verified through multi-disciplinary review to ensure accuracy and relevancy for clinical use. Every illustration provides detailed anatomic depictions to clarify critical structures and to allow the reader to instantly visualize the progressive extent of malignant disease. In addition, nodal maps are included for each site, appropriate labeling has been incorporated to identify significant anatomic structures, and each illustration is accompanied by an explanatory legend. The AJCC Cancer Staging Atlas, 2nd Edition, is an official publication of the American Joint Committee on Cancer, the recognized international leader in state-of-the-art information on cancer staging. This Atlas has been created as a companion to the updated 7th Edition of the AJCC Cancer Staging Manual, which continues to disseminate the importance of anatomical and pathological staging in the management of cancer. This state-of-the-art, invaluable 2nd Edition includes a CD containing PowerPoint slides of all illustrations, additional color, and a user-friendly, easy-to-read layout. The AJCC Cancer Staging Atlas, 2nd Edition will serve as an indispensable reference for clinicians, registrars, students, trainees, and patients.

The Union for International Cancer Controls (UICC) TNM classification system is the most widely used cancer classification and staging system in the world. It is used to describe the anatomical extent of disease and it is essential to patient care, research and cancer control. This fifth edition of the TNM Supplement: A Commentary of Uniform Use offers practitioners a wealth of material intended to complement the systems day-to-day use. The volume features: Updated definitions of terms used in cancer staging. New sections on carcinomas of the thymus, sarcomas of the spine and pelvis and soft tissue sarcomas of the head and neck, and comprehensive updates to the head and neck carcinomas, carcinomas of the lung and neuroendocrine tumours sections. Frequently asked questions from the UICC helpdesk. The Supplement may be treated as a companion text to the recent eighth edition of the TNM Classification of Malignant Tumours (978-1-119-26357-9), supporting the correct and uniform application of the TNM classification system. The TNM Supplement can also be utilised as a standalone book, providing explanations and examples to answer many questions that arise during the daily use of the TNM cancer classification and staging system, particularly in unusual cases.

The IASLC Atlas of ALK and ROS1 Testing in Lung Cancer is a resource designed to help pathologists, laboratory scientists, and practicing physicians better understand the background, protocol, and interpretation of results of ALK and ROS1 testing for patients with advanced non-small cell lung cancer.

Tumor Board Reviews provides comprehensive coverage of all topics in oncology. Each of the 32 chapters focuses on a specific major disease. A brief overview of epidemiology and risk factors is followed by a sequence of specific presentations organized by tumors stage or disease classification. Each discussion features a case presentation that mimics the format of a tumor board presentation and thus illustrates key diagnostic and management decisions. There is also a discussion of the evidence that supports the clinical management decisions taken in the case, based on current expert panel guidelines. Algorithms and decision tree graphics are used extensively to provide visual support of the decision process. The combination of case presentations and evidence-based management discussions make this volume a unique tool for keeping current with clinical guidelines and provides the reader with a clear understanding of applications of new information for use in daily practice.

Stereotactic body radiation therapy (SBRT) has emerged as an important innovative treatment for various primary and metastatic cancers. This book provides a comprehensive and up-to-date account of the physical/technological, biological, and clinical aspects of SBRT. It will serve as a detailed resource for this rapidly developing treatment modality. The organ sites covered include lung, liver, spine, pancreas, prostate, adrenal, head and neck, and female reproductive tract. Retrospective studies and prospective clinical trials on SBRT for various organ sites from around the world are examined, and toxicities and normal tissue constraints are discussed. This book features unique insights from world-renowned experts in SBRT from North America, Asia, and Europe. It will be necessary reading for radiation oncologists, radiation oncology residents and fellows, medical physicists, medical physics residents, medical oncologists, surgical oncologists, and cancer scientists.

This book offers an updated review of malignant mesothelioma, including the latest advances in our understanding of its genetic control and molecular biology, as well as pre-clinical and clinical research. It also presents state-of-the-art diagnostic approaches and therapeutic options, and an open discussion on the future prospects for patient management. Malignant mesothelioma is an enormous global health problem related to asbestos exposure. Despite the best efforts of scientists and oncologists, the prognosis for those affected remains poor. Due to anatomical characteristics and non-specific symptoms, the diagnosis of mesothelioma at an early stage is often difficult, while surgery and radiotherapy are only of limited use, even if some multimodality approaches seem promising. In turn, medical treatments are sometimes successful in tumor control, but have little impact on overall survival. However, advances in our understanding of the disease’s biology, together with the availability of new drugs and combinations, make mesothelioma an essential and highly topical field for pre-clinical and clinical studies. This book is subdivided into four parts: epidemiology and preclinical data, diagnosis, therapy, and extrathoracic mesothelioma. It highlights the progress made in a variety of areas – e.g. in vitro and in vivo experimental models, genetics, environment, biomarkers, targeting agents, immunotherapy, metabolic imaging and ongoing clinical trials – and describes the standard clinical management of mesothelioma patients, including those with extra-thoracic localizations. Given its scope, the book offers an invaluable tool for researchers, oncologists and clinicians alike.